Brief: Replicel Life Sciences qtrly loss per share C$0.14
Aug 30 (Reuters) - Replicel Life Sciences Inc RP.V :
* Qtrly loss per share C$0.14
* Says will require additional funding to continue research
and development activities, which casts substantial doubt about
co's ability to continue as going concern
Source text for Eikon: ID:nEOL11tYrq
Further company coverage: RP.V
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Replicel Life Sciences
See all newsBrief: Replicel Life Sciences Announces Reinstatement Of Trading & Conditional Acceptance For Proposed Transaction
Brief: Replicel Life Sciences Says Replicel Announces A Letter Of Intent For Asset Purchase Agreement
Brief: Replicel Announces Binding Term Sheet For Strategic Investment And U.S. Partnership
Brief: Replicel Announces Its Incoming Board Of Directors
Brief: RepliCel Life Sciences Retains Dermatology Sales And Marketing Executive To Guide Global Commercial Strategy For Automated Dermal Injector